Buspirone vs amitriptyline in the treatment of chronic tension-type headache

Mitsikostas, Dimos D.; Gatzonis, Stylianos; Thomas, A.; Ilias, A.

doi:10.1111/j.1600-0404.1997.tb00277.x

Cited by 30 publications

(18 citation statements)

References 14 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also recommended in case of comorbidity with anxiety, insomnia, depression or migraine [219, 220]. Amitriptyline is utilized at much lower dose for TTH than that necessary to obtain an antidepressive effect.…”

Section: Tension-type Headache (Tth)mentioning

confidence: 99%

See 1 more Smart Citation

Italian guidelines for primary headaches: 2012 revised version

et al. 2012

View full text Add to dashboard Cite

The first edition of the Italian diagnostic and therapeutic guidelines for primary headaches in adults was published in J Headache Pain 2(Suppl. 1):105–190 (2001). Ten years later, the guideline committee of the Italian Society for the Study of Headaches (SISC) decided it was time to update therapeutic guidelines. A literature search was carried out on Medline database, and all articles on primary headache treatments in English, German, French and Italian published from February 2001 to December 2011 were taken into account. Only randomized controlled trials (RCT) and meta-analyses were analysed for each drug. If RCT were lacking, open studies and case series were also examined. According to the previous edition, four levels of recommendation were defined on the basis of levels of evidence, scientific strength of evidence and clinical effectiveness. Recommendations for symptomatic and prophylactic treatment of migraine and cluster headache were therefore revised with respect to previous 2001 guidelines and a section was dedicated to non-pharmacological treatment. This article reports a summary of the revised version published in extenso in an Italian version.

show abstract

Section: Tension-type Headache (Tth)mentioning

confidence: 99%

“…Buspirone, a non-benzodiazepine anxyolitic drug, has been compared to amitriptyline, showing moderate results in a small sample of patients [220]. Further investigation is needed (level of recommendation III).…”

Section: Tension-type Headache (Tth)mentioning

confidence: 99%

Italian guidelines for primary headaches: 2012 revised version

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The tricyclic antidepressant (TCA) amitriptyline has been widely studied as a prophylactic treatment for TTH . As with the use of TCAs in depression, the symptom reduction associated with TCA treatment must be balanced with their poor safety and tolerability profiles (13–19). Most TCAs are believed to act by inhibiting the neuronal reuptake of serotonin (5‐HT) and norepinephrine (NE) in the central nervous system, while also showing an affinity for the α 1 ‐adrenergic, H1 histamine and muscarinic receptors (20).…”

Section: Introductionmentioning

confidence: 99%

“…cardiotoxicity, death with overdose and a potential for dangerous drug–drug interactions). Amitriptyline treatment is associated with a number of side‐effects (14–20).…”

Section: Introductionmentioning

confidence: 99%

A Randomized, Double-Blind, Placebo-Controlled Study of Venlafaxine XR in Out-Patients With Tension-Type Headache

et al. 2007

View full text Add to dashboard Cite

The aim of this study was to evaluate in a double-blind, randomized, placebo-controlled study the safety and efficacy of venlafaxine extended release (XR) in the prophylactic treatment of out-patients with tension-type headache (TTH) and no current depression or anxiety disorders. Sixty neurology and headache clinic out-patients meeting the International Headache Society diagnostic criteria for TTH were treated with venlafaxine XR (150 mg/day, n = 34) or placebo (n = 26) for 12 weeks. The primary efficacy variable was the decline in number of days with headache. At end-point, the venlafaxine XR group had a significantly greater decrease in the number of days with headache compared with placebo (P = 0.05). Differences with regard to secondary efficacy variables where not significant. The number needed to treat for responders (>or=50% reduction in days with headache) was 3.48. Six patients in the venlafaxine XR group interrupted therapy due to adverse events, while no patients in the placebo group did so for the same reason. The number needed to harm was 5.58. This study provides preliminary evidence for the efficacy and safety of venlafaxine XR 150 mg/day in reducing the number of days with TTH.

show abstract

“…Amitriptyline 50 mg/day was compared with buspirone 30 mg/day, but the study did not involve a placebo arm [58].…”

Section: Scientific Evidencementioning

confidence: 99%

Pharmacotherapy of tension-type headache (TTH)

Lenaerts

2009

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

In this article, we review the existing literature on medications and make practical recommendations based on the evidence of their efficacy. We review both abortive and prophylactic medications (such as tricyclic antidepressants and non-steroidal anti-inflammatory drugs, respectively). Both are used for chronic TTH and abortive medications only for infrequent episodic TTH (ETTH). As far as frequent ETTH, abortive medications are used and prophylactic medications often but not systematically. We comment and advise on general therapeutic principles of TTH management.

show abstract

Buspirone vs amitriptyline in the treatment of chronic tension-type headache

Cited by 30 publications

References 14 publications

Italian guidelines for primary headaches: 2012 revised version

Italian guidelines for primary headaches: 2012 revised version

A Randomized, Double-Blind, Placebo-Controlled Study of Venlafaxine XR in Out-Patients With Tension-Type Headache

Pharmacotherapy of tension-type headache (TTH)

Contact Info

Product

Resources

About